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Severe steroid-refractory acute graft-versus-host disease (aGVHD) is related to signiﬁcant mortality and
morbidity after allogeneic stem cell transplantation. Early clinical trials of therapy with human mesenchymal
stem cells (hMSCs) in pediatric patients with severe aGVHD resistant to multiple immunosuppressive agents
showed promising results. In this study, we evaluated the risk/beneﬁt proﬁle of remestemcel-L (Prochymal), a
third-party, off-the-shelf source of hMSCs, as a rescue agent for treatment-resistant aGVHD in pediatric pa-
tients. Children with grade B-D aGVHD failing steroids and, in most cases, other immunosuppressive agents
were eligible for enrollment. Patients received 8 biweekly i.v. infusions of 2  106 hMSCs/kg for 4 weeks, with
an additional 4 weekly infusions after day þ28 for patients who achieved either a partial or mixed response.
The enrolled patients compose a very challenging population with severe disease that was nonresponsive to
the standard of care, with 88% of the patients experiencing severe aGVHD (grade C or D). Seventy-ﬁve pa-
tients (median age, 8 yr; 58.7% male; and 61.3% Caucasian) were treated in this study. Sixty-four patients
(85.3%) had received an unrelated hematopoietic stem cell graft, and 28 patients (37.3%) had received a cord
blood graft. At baseline, the distribution of aGVHD grades B, C, and D was 12.0%, 28.0%, and 60.0%, respec-
tively. The median duration of aGVHD before enrollment was 30 d (range, 2 to 1639 d), and patients failed a
median of 3 immunosuppressive agents. Organ involvement at baseline was 86.7% gastrointestinal, 54.7%
skin, and 36.0% liver. Thirty-six patients (48.0%) had 2 organs involved, and 11 patients (14.7%) had all 3 or-
gans involved. When stratiﬁed by aGVHD grade at baseline, the rate of overall response (complete and partial
response) at day þ28 was 66.7% for aGVHD grade B, 76.2% for grade C, and 53.3% for grade D. Overall response
for individual organs at day þ28 was 58.5% for the gastrointestinal system, 75.6% for skin, and 44.4% for liver.
Collectively, overall response at day þ28 for patients treated for severe refractory aGVHD was 61.3%, and this
response was correlated with statistically signiﬁcant improved survival at day þ100 after hMSC infusion.
Patients who responded to therapy by day þ28 had a higher Kaplan-Meier estimated probability of 100-
d survival compared with patients who did not respond (78.1% versus 31.0%; P < .001). Prochymal in-
fusions were generally well tolerated, with no evidence of ectopic tissue formation.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
The success of allogeneic hematopoietic stem cell trans-
plantation (HSCT) and its ultimate therapeutic effect de-
pends on the control of acute graft-versus-host disease
(aGVHD). Depending on various risk factors and the admin-
istration of prophylactic agents, 30% to 80% of recipients willdgments on page 235.
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13.11.001develop aGVHD [1,2]. Corticosteroids are the initial inter-
vention for controlling aGVHD; however, in 30% to 50% of
patients, aGVHD is not controlled with ﬁrst-line therapy and
requires additional therapeutic intervention [3]. In a recent
retrospective analysis of 864 patients with aGVHD [4], pa-
tients who failed to respond to therapy at day þ28 after
initiation were 2.78 times more likely to experience
treatment-related mortality (TRM) compared with those
who demonstrated response. Thus, the outcomes for non-
responders are poor. Various agents have been added toTransplantation.
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aGVHD, including polyclonal and monoclonal antibodies,
immunotoxins, immunosuppressive agents, chemothera-
peutic agents, and phototherapy. Overall, responses to these
agents and outcomes in salvage therapy for steroid-
refractory aGVHD have been disappointing [5-7].
Clinically, patients who fail to respond to steroids and
additional immunosuppressive agents are at increased risk
for morbidity associated with infections and uncontrolled
aGVHD, as well as an increased risk of mortality. The poor
prognosis of severe aGVHD is well documented, with long-
term survival probabilities of 20% for grade III and <5% for
grade IV [8]. Thus, steroid-refractory aGVHD represents a
signiﬁcant clinical challenge.
Previous studies have demonstrated the potential of
human mesenchymal stem cells (hMSCs) as an effective
treatment for aGVHD. Recent reviews indicate that hMSCs
down-regulate immune and inﬂammatory responses,
providing therapeutic potential for treating diseases charac-
terized by the presence of an inﬂammatory component
[9,10]. The production of anti-inﬂammatory cytokines and
growth factors by hMSCs can promote a favorable environ-
ment and facilitate tissue repair. Clinical improvement in
aGVHD after i.v. infusion of hMSCs has been reported in
single case reports [11], pilot studies [12-15], and phase II
studies [16,17]. In these studies, the vast majority of patients
received 1 or 2 infusions of hMSCs. Clinical experience and
pilot investigations have indicated that for the most severe
cases of refractory aGVHD, a greater number of treatments
may be required to reverse the course of one of the most
severe complications of HSCT [14]. Here we present the
ﬁndings of a study of severe, multiline refractory aGVHD in
pediatric patients treated with multiple infusions of alloge-
neic culture-expanded adult hMSCs (remestemcel-L [Pro-
chymal]; Osiris Therapeutics, Columbia, MD).
METHODS
Study Design
This was an open-label, single-arm, prospective multicenter study of
male and female pediatric patients between age 2 mo and 17 yr (inclusive)
with grade B-D aGVHD [18] who were nonresponsive to steroids and, in
most cases, other immunosuppressive therapies. The objectives were to
evaluate whether the treatment plan (8 infusions of 2  106 hMSCs/kg)
could induce an objective response in patients with severe refractory
aGVHD, and also to assess the safety and tolerability of remestemcel-L
infusion for the given dosing scheme.
As part of this trial, aGVHD prophylactic agents, concomitant therapies,
and other supportive therapies were administered at the investigator’s
discretion in accordance with site-speciﬁc institutional practices and pol-
icies. Safety assessments included 12-lead electrocardiography, and moni-
toring for infusional toxicity, ectopic tissue formation, relapse of underlying
malignancy, and survival. Serious adverse events (SAEs) were recorded
throughout the study. Patients were evaluated for the efﬁcacy and safety of
remestemcel-L until death, withdrawal, or 100 d after the ﬁrst infusion (day
0), whichever occurred ﬁrst.
Study Population
Pediatric patients (age 2 mo to 17 yr; median age, 7.8 yr) with aGVHD
secondary to allogeneic HSCT or donor lymphocyte infusion who had failed
to respond to systemic steroid therapy for grade B-D aGVHD (using the
Center for International Blood and Marrow Transplant Registry grading
scheme [18]) were eligible. Failure to respond to steroid treatment for
aGVHD was deﬁned as any grade II-IV aGVHD that did not improve after at
least 3 d of treatment with methylprednisolone (1 mg/kg/d) or equivalent.
Exclusion criteria included known allergy to bovine or porcine products and
most recent HSCT performed to treat a solid tumor. In addition, patients
must not have had evidence of a pulmonary inﬁltrate or diffuse alveolar
hemorrhage, and must have been deemed unlikely to require more than 2 L
of oxygen via face mask or an estimated fraction of inspired oxygen of 28%
via other delivery methods to maintain oxygen saturation of 92% for the 3 d
after screening.The protocol was submitted for ethics review, and approval or
acknowledgment of treatment was obtained in writing from the Institu-
tional Review Board or Ethics Committee of each institution. Parental signed
informed consent and patient assent, when applicable, were required before
any study-speciﬁc procedures were undertaken. The study was registered
with www.ClinicalTrials.gov (NCT00759018).
Failed aGVHD Therapy
The number of therapies beyond systemic steroid therapy that each
patient received before the start of remestemcel-L was recorded. Previous
aGVHD therapies included systemic steroids (methylprednisolone or
equivalent), inﬂiximab, etanercept, pentostatin, daclizumab, rituximab,
denileukin diftitox, alemtuzumab, mycophenolate mofetil, tacrolimus, and
antithymocyte globulin. Nonsystemic steroids, such as budesonide and
beclamethasone, were not counted as second-line therapy for aGVHD
treatment, nor were prophylactic treatments, such as cyclosporine, siroli-
mus, and methotrexate. If an agent was used for aGVHD prophylaxis, dis-
continued, and then restarted for treatment, therapy must have been
initiated after the onset of aGVHD for the agent to be counted as a second-
line agent for aGVHD.
The effect of aGVHD therapies before the introduction of remestemcel-L
was characterized as improving, unchanged, or worsening. Improving
aGVHD was deﬁned as at least a 1-grade reduction in aGVHD between
disease onset and study baseline, worsening GVHD was deﬁned as an in-
crease in aGVHD grade, and maximal aGVHDwas deﬁned as grade D at both
onset and study baseline.
Treatment Regimen
Remestemcel-L was given i.v. at a dose of 2  106 hMSCs/kg of body
weight twice weekly for 4 consecutive wk. Patients received all 8 infusions
in the initial treatment plan by day þ28. Infusions were administered at
least 3 d apart. During the course of remestemcel-L treatment, all other
aGVHD therapies were administered at the discretion of the investigator
according to institutional practice.
Patients who demonstrated a partial response (PR) or mixed response
(MR) to remestemcel-L at study day þ28 and had no safety issues related to
therapy after the ﬁrst 8 doses were eligible for continued therapy with an
additional 4 infusions of 2  106 hMSCs/kg administered once weekly for
4 wk.
Within 30 min before remestemcel-L infusion, patients were pre-
medicated with hydrocortisone (0.5-1.0 mg/kg, up to 50 mg/dose) and
diphenhydramine (0.5-1mg/kg, up to 50mg/dose). The product was thawed
and reconstituted with PlasmaLyteA (Baxter, Deerﬁeld, Illinois) to a ﬁnal cell
concentration of 2.5  106 hMSCs/mL. The dimethyl sulfoxide (DMSO)
concentration of the ﬁnal infused product was 3.75%. The infusionwas given
i.v. at a controlled rate of 4-6 mL/min in patients weighing 35 kg and over
60 min in those weighing <35 kg. The total volume administered to each
patient was dependent on body weight. Vital signs and oxygen saturation
were monitored during each infusion. Oxygen saturation was monitored by
pulse oximetry for at least 30 min before and up to 2 hr after the start of
infusion.
All patients received standard of care treatment with corticosteroids, as
well as other second-line agents at the discretion of the investigator.
Source of hMSCs, Remestemcel-L
The product lots of remestemcel-L used in this study were derived from
the bonemarrow of 7 different donors, age 18-30 yr, who had been screened
and tested in accordance with Food and Drug Administration requirements
for blood and tissue-based products. The product lots were manufactured
using a scaled adaptation of the technique described by Pittenger et al. [19]
in accordance with good manufacturing practices, as described previously
[17]. All lots met established quality release criteria for viral pathogens,
mycoplasma, sterility, endotoxin, cell identity, purity, viability, and potency
before use.
GVHD Assessment
The severity of aGVHD was assessed using the Center for International
Blood and Marrow Transplant Research grading system [18]. Patients were
evaluated by the treating physician for the presence or absence of aGVHD of
the skin, liver, and gastrointestinal (GI) system. Organ stage and overall
grade were recorded. aGVHD assessments were performed at baseline
before initiation of remestemcel-L, at day þ28 after initiation, and at
day þ100/end of treatment.
Response to treatment was evaluated based on established clinical
criteria [4]. Overall response (OR) was either a complete response (CR) or a
PR. No response (NR) was deﬁned as a MR, stable disease, or worsening




No. of patients 75
Age, yr
Mean (SD) 8.6 (5.78)





American Indian or Alaska Native 1 (1.3)
Asian 5 (6.7)
Black or African American 15 (20.0)




Mean (SD) 32.1 (20.54)
Median (range) 26.9 (5.4-103.7)
Underlying disease, n (%)
Malignant 45 (60.0)
Nonmalignant 30 (40.0)






Genetic disease 16 (21.3)
Other 16 (21.3)
Donor type, n (%)
Unrelated 64 (85.3)
Related 11 (14.7)
Donor compatibility, n (%)
HLA-matched 39 (52.0)
HLA-mismatched 36 (48.0)
HSCT graft source, n (%)*
Bone marrow 25 (33.3)
PBSCs 16 (21.3)
Cord blood 28 (37.3)
Donor lymphocyte infusion 5 (6.7)




Complete response (CR) Resolution of aGVHD in all involved organs
Partial response (PR) Organ improvement of at least 1 stage
without worsening in any other organ system
Overall response (OR) CR or PR
Mixed response (MR) Improvement by at least 1 organ stage in at
least 1 evaluable organ with worsening by at
least 1 organ stage in at least 1 other organ
Stable disease The absence of any clinically signiﬁcant
differences (improvement or worsening)
sufﬁcient to meet minimal criteria for
improvement or deterioration in any
evaluable organ
Worsening disease Deterioration in at least 1 evaluable organ
by 1 stage or more
No response MR or stable disease or worsening disease
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experiencing an MR or NR or who died on or before day þ28 were counted
as nonresponders at day þ28.
Statistical Analysis
Objective assessment of the response of aGVHD to treatment with
remestemcel-L was determined as the OR rate at day þ28. To present
changes in aGVHD organ stage, response data from baseline to day þ28 was
classiﬁed for each organ as improving, stable, progressing, or death.
To assess the effect of continuing therapy (>8 infusions), response from
day þ28 to day þ100 was summarized, stratiﬁed by aGVHD grade at base-
line and overall. To evaluate the effect of response on overall survival,
2 Kaplan-Meier survival analyses were conducted through day þ100. A
Kaplan-Meier curve was generated for patients who had achieved OR at
dayþ28, and another Kaplan-Meier curve was generated for nonresponders
at day þ28. The null hypothesis of no difference in overall survival between
the 2 groups was tested with the log-rank test using PROC LIFETEST in SAS
(SAS Institute, Cary, NC). The testing was performed at a signiﬁcance level of
P < .05.
Categorical variables were summarized as frequencies and percentages.
Continuous variables were summarized using descriptive statistics (number,
mean, standard deviation [SD], median, and range). All conﬁdence intervals
had a 95% conﬁdence level.RESULTS
Patient Characteristics
Seventy-ﬁve pediatric patients were enrolled in 7 coun-
tries (the United States, Canada, the United Kingdom, Italy,
Finland, New Zealand, and Australia). A median of 10.0 doses
(range, 1 to 20) was administered, with all patients receiving
at least 1 infusion. Patient characteristics are summarized
in Table 2. The study cohort comprised 44 males (58.7%) and
31 females (41.3%), with a median age of 7.8 yr (range, 0.2 to
17.5 yr). Forty-ﬁve patients (60.0%) underwent HSCT for a
hematologic malignancy, and the remaining patients un-
derwent HSCT for nonmalignant disease, primarily of genetic
origin. The most common underlying malignancies or
leukemic diseases at the time of transplantation were acute
lymphoblastic leukemia (ALL; n ¼ 18, 24.0%) and acute my-
elogenous leukemia (AML; n¼ 16, 21.3%). The majority of the
HSCT graft donors were unrelated (85.3%), nearly evenly
divided between HLA-matched (52%) and HLA-mismatched
(48%).
Baseline aGVHD disease characteristics are detailed in
Table 2. The median time from HSCT to aGVHD onset was
28.0 d (range, 7 to 270 d). At the time of onset, 33.3% of pa-
tients had grade C aGVHD and 32.0% had grade D aGVHD. At
the start of remestemcel-L treatment, the vast majority of
patients (88%) had grade C (28.0%) or grade D (60.0%) aGVHD,
indicating the aggressive nature of their disease. Sixty-ﬁvepatients (86.7%) experienced GI aGVHD, 39 (52.0%) with
maximal GI involvement (stage 4). Forty-one patients (54.7%)
had skin involvement, and 27 (36.0%) had liver involvement.
Approximately one-half of the patients had 2 organs
involved, and 14.7% of had all 3 organs (skin, liver, and GI
system) involved.Previous Failed aGVHD Therapy
The median time from aGVHD onset to the start of
remestemcel-L treatment was 30 d. In the interval between
aGVHD onset and initiation of remestemcel-L, patients were
maintained on aGVHD prophylaxis, systemic steroids, and, in
many cases, 1 or more second-line agents for the treatment
of aGVHD (Table 3). All patients were refractory to steroid
therapy. The majority (60.0%) received 2 or more additional
aGVHD agents after failing steroids. The most common
agents were inﬂiximab (54.7%), tacrolimus (42.7%), daclizu-
mab (25.3%), andmycophenolatemofetil (24.0%). Virtually all
of the patients (96.0%) did not improve despite treatment
with steroids and other aGVHD immunosuppressive thera-
pies before study entry.GVHD Treatment Response
Patients’ responses to study treatment at day þ28 are
summarized in Tables 4 and 5. At day þ28, 46 patients




Number of patients 75
Interval from HSCT to GVHD onset, d
Mean (SD) 49.6 (54.02)
Median (range) 28.0 (7-270)
GVHD grade at baseline, n (%)
Grade B 9 (12.0)
Grade C 21 (28.0)
Grade D 45 (60.0)
Organ staging at baseline, n (%) Stage 0 Stage 1 Stage 2 Stage 3 Stage 4
Skin 34 (45.3) 6 (8.0) 15 (20.0) 14 (18.7) 6 (8.0)
GI 10 (13.3) 3 (4.0) 9 (12.0) 14 (18.7) 39 (52.0)
Liver 48 (64.0) 4 (5.3) 8 (10.7) 9 (12.0) 6 (8.0)




Two organ involvement, n (%) 36 (48.0)
GI, skin 23 (30.7)
GI, liver 13 (17.3)
Three organ involvement, n (%) 11 (14.7)
Interval from GVHD onset to ﬁrst infusion, d*
Mean (SD) 70.3 (190.51)
Median (range) 30.0 (2-1639)
Number of failed GVHD agents, n (%)
Systemic steroids only 12 (16.0)
One agent 18 (24.0)
Two agents 25 (33.3)
Three agents 12 (16.0)
Four or more agents 8 (10.7)





Denileukin diﬁtox 1 (1.3)
Alemtuzumab 2 (2.7)
Antithymocyte globulin 4 (5.3)
Mycophenolate mofetil 18 (24.0)
Tacrolimus 32 (42.7)
Rituximab 7 (9.3)
GVHD status before ﬁrst infusion, n (%)
Improving 2 (2.7)
Unchanged 22 (29.3)
Worsening or maximal GVHD 50 (66.7)
The date of GVHD onset was not available for 1 patient.
* The high SD and range are attributed largely to 1 patient who started treatment 1639 d after being diagnosed with GVHD. Omitting this patient, the time was
mean 48.8  46.39 d.
Table 4
Summary of Overall Response to Remestemcel-L at Day þ28








Responders, n (%) 6 (66.7) 16 (76.2) 24 (53.3) 46 (61.3)
Nonresponders, n (%) 3 (33.3) 5 (23.8) 21 (46.7) 29 (38.7)
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reduction. Overall, in 87% of the evaluable patients, no new
aGVHD medications were introduced after initiation of
remestemcel-L, and the response rate in these patients was
65.5%.
Individual organ response to remestemcel-L was assessed
from organ staging (Table 5). Among the 65 patients with
aGVHD of the lower GI tract at baseline, 70.7% were experi-
encing clinical symptoms consistent with severe (stage 3 to
4) GI aGVHD. At day þ28, 58.5% of these patients showed
improvement in their clinical symptoms, and 56.2% of the
patients experiencing severe GI aGVHD had a 2-grade
improvement in GI aGVHD. Seventeen patients (26.2%)
experienced complete resolution of GI aGVHD. Three pa-
tients (4.6%) with GI aGVHD at baseline experienced GI
aGVHD progression.
Of the 27 patients (36.0%) with liver aGVHD at baseline,
12 (44.4%) demonstrated improvement in liver disease at
day þ28, with 9 cases (33.3%) resolving completely. Two
patients (7.4%) with liver aGVHD at baseline experienced
progression of liver disease.Forty-one patients (54.7%) had skin aGVHD at baseline.
Fourteen of these patients had skin rash covering 50%-100%
of the body, and 6 patients had severe rash with bullae. At
day þ28, 31 patients (75.6%) showed improvement in skin
disease, with 43.9% of cases resolving completely. No pa-
tients with skin aGVHD at baseline experienced progression
of skin disease.Effects of Continuing Therapy
Patients were eligible for continued therapy if they had
either a PR or MR at day þ28. The beneﬁt of continuing
Table 5
GVHD Organ Stage Response by Baseline Organ Involvement at Day þ28
GI (n ¼ 65) Liver (n ¼ 27) Skin (n ¼ 41)
Complete resolution, n (%) 17 (26.2) 9 (33.3) 18 (43.9)
Improving, n (%) 21 (32.3) 3 (11.1) 13 (36.4)
Stable, n (%) 15 (23.1) 7 (25.9) 5 (12.2)
Progressing, n (%) 3 (4.6) 2 (7.4) 0 (0)
Death, n (%) 9 (13.8) 6 (22.2) 5 (12.2)
Only subjects with organ involvement at baseline (stage >0) are included in
the percentages.
Deﬁnitions: complete resolution, reduction to organ stage 0; improving,
reduction by at least 1 stage; stable, no change in the stage; progressing, an
increase by at least 1 stage.
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fusions) was assessed by aGVHD grade (Table 6). Only pa-
tients receiving continuing therapy were included in the
analysis. For a patient to be considered a responder to
continuing therapy, he or she must have experienced addi-
tional improvement in at least 1 organ of at least 1 stage
without worsening in any other organ between day þ28 and
day þ100. Patients who maintained a CR after day þ28 were
considered responders as well. Patients who had a PR at
day þ28 but experienced no change in organ staging
between day þ28 and day þ100 were considered
nonresponders.
Overall, 40 of 75 patients (53.3%) received more than 8
remestemcel-L infusions and were included in the
continuing therapy analysis. More than one-half of these
patients (57.5%) demonstrated additional improvement in
aGVHD, with 16 patients achieving complete resolution of
aGVHD.
Survival
The probability of survival from study entry based on
whether a patient was a responder or not at day þ28 was
estimated by Kaplan-Meier analysis (Figure 1). Of those pa-
tients with an OR at day þ28, 76.1% survived at least 100 d
past the ﬁrst infusion compared with 27,6% of patients
without an OR at day þ28. The log-rank test for the com-
parison of survival probability in responders versus non-
responders revealed a signiﬁcant 100-d survival advantage
for those patients with an OR at day þ28 (P < .001).
Overall survival at day þ100 was 57.3%. By aGVHD grade
at baseline, 66.7% of patients with grade B, 66.7% of those
with grade C, and 51.1% of those with grade D survived to
day þ100.
Safety
The remestemcel-L infusion was well tolerated by all
patients. The mean total number of infusions received was
9.7  3.97, with a median of 10.0 (range, 1 to 20). Thirty-ﬁve
patients (46.7%) received 8 infusions, and 40 patients
(53.3%) received >8 infusions. Duration of exposure rangedTable 6
Effect of Continuing Therapy with Remestemcel-L, Stratiﬁed by Baseline
Grade








Subjects with >8 infusions, n 5 13 22 40
Responders, n (%) 3 (60.0) 10 (76.9) 10 (45.5) 23 (57.5)
Nonresponders, n (%) 2 (40.0) 3 (23.1) 12 (54.5) 17 (42.5)from 0 d (1 patient received only 1 infusion) to 116 d, with a
mean of 40.5  24.59 d. Infusional toxicity was evaluated by
monitoring vital signs (heart rate, respiration rate, temper-
ature, and blood pressure) and oxygen saturation from
30 min before infusion to 2 hr after infusion. Only 1 patient
(1.3%) experienced an infusion-related reaction (ie, rise in
body temperature, increased breathing, and decreased oxy-
gen saturation) after the third and fourth infusions, which
resolved without sequelae.
Forty-six of the 75 patients (61.3%) reported at least 1 SAE,
and a total of 105 SAEs were reported (Table 7). The most
frequently reported SAEs were respiratory failure (in 7 pa-
tients; 9.3%), multiorgan failure (6 patients; 8.0%), and hy-
pertension and GVHD (3 patients each; 4.0%). One patient
experienced acute respiratory distress that led to study
withdrawal. No patients experienced an SAE deemed likely
or deﬁnitely related to remestemcel-L by the investigator.
Seven SAEs in 6 patients were considered possibly related:
neutropenia in 1 patient, tachycardia in 1, infusion-related
reaction (2 events) in 1, respiratory distress in 1, pulmo-
nary hemorrhage in 1, and hypertension in 1 (all 1.3%).
By system organ class, the most common SAEs leading to
death were respiratory, thoracic, and mediastinal disorders,
of which the most frequent was respiratory failure (5 pa-
tients; 6.7%). Other frequent SAEs leading to death were
multiorgan failure (4 patients; 5.3%) and aGVHD, mucormy-
cosis, and aspergillosis (2 patients each; 2.7%). Two deaths
were associated with relapse of the underlying malignancy
(ALL and AML).
Patients weremonitored for ectopic tissue formationwith
computed tomography scans before the ﬁrst infusion and at
the day þ100 visit. No ﬁndings indicating ectopic tissue
formation were detected, and no SAEs possibly representing
ectopic tissue foci were reported. In addition, there were no
remarkable post-treatment electrocardiography ﬁndings.
DISCUSSION
We report the results of a single-arm, multi-institutional
study of remestemcel-L in pediatric patients with severe
end-stage aGVHD who had exhausted conventional treat-
ment options. This is the largest prospective study of its kind
reported to date in pediatric patients with severe, multiline
refractory aGVHD. The enrolled patients composed a very
challenging population suffering from severe disease that
was nonresponsive to steroids and, in most cases, other
immunosuppressive agents. Their aGVHD was aggressive in
nature, with 65% of the patients experiencing severe (grade
C/D) aGVHD at disease onset. At study baseline, 88% of the
patients had severe aGVHD, 91% with visceral organ
involvement and 63% with multiorgan involvement. Despite
aggressive treatment for a median of 30 d before initiation of
remestemcel-L treatment, 96% of the patients were wors-
ening or not improving at study entry.
Owing to the aggressive refractory nature of aGVHD in
these patients, the achievement of a substantial level of
response is a meaningful and positive observation. In this
study, 61% of the patients responded to remestemcel-L treat-
ment at day þ28. The vast majority (87%) of the patients did
not receive any new aGVHD medication during the
remestemcel-L treatment window. Clinical response was
observed across all grades of aGVHD, with 67% of patients with
grade B, 76% of thosewith grade C, and 53% of thosewith grade
D demonstrating response at dayþ28. Objective improvement
was also observed in all organ systems, with 76% of skin cases,
58% of GI cases, and 44% of liver cases improving at day þ28.
Figure 1. Kaplan-Meier plot of survival from study entry based on whether the patient was a responder or a nonresponder at day þ28. The log-rank test for the
comparison of survival probability for responders versus nonresponders demonstrated a signiﬁcant 100-d survival advantage for responders (P < .001). Two patients
(1 responder and 1 nonresponder) who completed the study before day þ100 (at day þ92 and day þ99) were censored.
J. Kurtzberg et al. / Biol Blood Marrow Transplant 20 (2014) 229e235234Given that incomplete responses at day þ28 could be
associated with either continued improvement or progres-
sion at subsequent time points, response by day þ100 was
also assessed, and was found to be 77%.
Continued therapy beyond the initial regimen of 8
biweekly infusions proved beneﬁcial. The treatment of 40 pa-
tients beyond the initial 8 infusions produced 23 additional
ORs (57.5%), including 16 patients with complete resolution of
aGVHD.
Available data for pediatric patients with refractory
aGVHD are limited, consisting primarily of retrospective
studies generally of fewer than 20 patients treated with
daclizumab [20-23] or inﬂiximab [24,25]. In a daclizumab
study of steroid-refractory aGVHD reporting data at day þ28,
responsewas observed in 6 of 17 patients (35%) overall, and a
relationship between response and survival was seen, with 5
of 6 responding patients surviving [22]. Overall median
survival was 60 d after initiation of daclizumab, demon-
strating the life-threatening nature of aGVHD. In a study of
inﬂiximab in 18 pediatric patients with less severe aGVHD
comparedwith the present study (39% with grade I/II aGVHD
and 61% with grade III/IV aGVHD), survival ranged from 40%
to 62% at day þ100 after initiation of inﬂiximab [25].
In the largest double-blind, placebo-controlled, ran-
domized study of hMSCs for treating steroid-refractory
aGVHD reported to date [26,27], a subset of 28 pediatric
patients had a day þ28 OR rate of 64% for the Prochymal
group versus 36% for the standard of care treatment group,
very similar to our present results. The patient populations
in the 2 studies had comparably severe disease, with 79% of
the 28-patient pediatric subset entering the study with
grade III or IV aGVHD.Table 7
Summary of SAEs
Subjects (n ¼ 75), n (%) Events, n
Subjects with at least 1 SAE 46 (61.3) 105
Relationship to study drug
Possibly related 6 (8.0) 7
Not related 40 (53.3) 98
Severity grade
Mild (grade 1) 0 (0.0) 2
Moderate (grade 2) 4 (5.3) 12
Severe (grade 3) 6 (8.0) 39
Life-threatening (grade 4) 6 (8.0) 20
Death (grade 5) 30 (40.0) 32
Subjects with an SAE leading
to withdrawal
1 (1.3) 1The best-documented 28-d response rate for the treat-
ment of aGVHD is for the use of high-dose systemic corti-
costeroids as ﬁrst-line therapy [4]. The response rate in that
study was 65%, essentially identical to the response rate
obtained in the present study, even though the steroid data
were collected from a patient population (n ¼ 864) with
signiﬁcantly milder disease (85% with grade I or II aGVHD,
14% with grade III, and only 1% with grade IV). In contrast, in
the present study, 60% of the patients had grade D aGVHD at
the time of enrollment.
In the present study, the treatment regimen led to re-
sponses and an objective clinical beneﬁt in severe refractory
aGVHD. Multiple infusions were administered to treat severe
refractory aGVHD for several reasons. The extensive inﬂam-
mation occurring in severe aGVHD may limit the persistence
of hMSCs [28], thus requiring additional infusions to quell
the active ongoing inﬂammatory response. In addition,
although not assessed in these patients, multiple dosing may
promote tolerance of the stem cell graft through such
mechanisms as increased numbers of regulatory T cells
[29,30]. Other investigations have implemented multiple
infusions over the course of several weeks to prolong the
therapeutic effect of hMSCs [31].
Response to treatment at day þ28 is an important
endpoint with a proven link to the probability of survival.
According to a recent consensus of experts, response to
treatment at day þ28 is the most relevant endpoint for
evaluation of aGVHD therapy, because it is an important
predictor of later survival [32]. Recently reported data have
conﬁrmed that overall response is correlated with improved
survival in patients with aGVHD [4]. Our present data sup-
port that relationship. Survival to day þ100 after the ﬁrst
infusion of remestemcel-L was improved in the patients who
responded at day þ28. Of the 46 patients who experienced
an OR at day þ28, 35 (76%) survived to day þ100, compared
with only 8 of the 29 nonresponders (28%). The effect on
survival of achieving a response at day þ28 was highly sig-
niﬁcant (P < .001).
Remestemcel-L appears to have a benign safety proﬁle.
Infusions were well tolerated, with only 2 reported reactions
occurring in the same patient out of more than 500 infusions
administered during the course of the study. There were no
cases of ectopic tissue formation. The number and type of
events reported are consistent with a severely immuno-
compromised aGVHD patient population. At study entry,
these patients have a complicated history and suffer from a
variety of severe medical conditions. Treatment with
J. Kurtzberg et al. / Biol Blood Marrow Transplant 20 (2014) 229e235 235remestemcel-L did not lead to apparent additional toxicities
and was well tolerated in this population. Furthermore, this
therapy was not associated with hematologic or renal
toxicity, which is commonly seen with other approaches to
aGVHD prophylaxis or treatment.
The prognosis of severe refractory aGVHD remains poor,
and better therapies for these patients are urgently needed.
Remestemcel-L is a promising alternative to second-line
immunosuppressive agents. The risk/beneﬁt proﬁle for
remestemcel-L for the treatment of this life-threatening
disease is in favor of treatment, based on the high observed
response rates and positive safety proﬁle.
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